Postmarketing Surveillance Study of EVENITY (Romosozumab) in South Korea (20170753)

First published 19/07/2019

Last updated 05/02/2025

EU PAS number:

EUPAS30346

Study

Ongoing

Download as PDF

Documents

Study protocol

Updated protocol

Protocol-Published Superseding romosozumab 20170753 2 .pdf

First published: 07/11/2024

English (4.25 MB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents